Structured evidence table for Berberine Triglycerides Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Berberine Triglycerides Meta-Analysis | As such, it may be beneficial to use berberine combined with statins in people with hyperlipidemia, especially for those with statin intolerance or partial intolerance, and those with diabetes or at high risk of diabetes. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Triglycerides Meta-Analysis | Berberine has been recommended by the International Lipid Expert Panel and the 2019 European Atherosclerosis Society/European Society of Cardiology Guidelines for the treatment of hyperlipidemia in statin-intolerant patients, however, these guidelines have not provided explicit recommendations about the use of berberine because of the lack of high-quality evidence. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Triglycerides Meta-Analysis | Despite of the benefits on lipid profile and glucose metabolism, the effect of berberine on the risk of IHD and diabetes has not been clarified. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Triglycerides Meta-Analysis | 1 2 3 4 Ischemic heart disease (IHD) is the single leading cause of mortality and poses a heavy burden on healthcare, which accounts for ~16% of all deaths globally. | 2 | Zhao Jie V. (2026) | Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization |
| Berberine Triglycerides Meta-Analysis | 1 2 3 4 5 6 7 8 9 10 The concept of metabolic syndrome was first introduced in 1988 as “Syndrome X” to describe the frequent clustering of insulin resistance with metabolic abnormalities that increase the risk of type 2 diabetes mellitus and cardiovascular disease [,]. | 3 | Starvaggi Josè (2026) | Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications |
| Berberine Triglycerides Meta-Analysis | This definition identifies metabolic syndrome based on the presence of at least three of the following components: increased waist circumference (population specific), hypertriglyceridemia and/or reduced HDL cholesterol, elevated blood pressure, and impaired fasting glucose [,]. | 3 | Starvaggi Josè (2026) | Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications |
| Berberine Triglycerides Meta-Analysis | 15 16 17 14 18 Accumulating evidence indicates that fat distribution rather than total adiposity is the principal determinant of metabolic risk. | 3 | Starvaggi Josè (2026) | Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications |
| Berberine Triglycerides Meta-Analysis | The term was later refined to “metabolic syndrome” to avoid confusion with cardiac Syndrome X and to better reflect the underlying metabolic dysregulation []. | 3 | Starvaggi Josè (2026) | Selected Nutraceuticals in Metabolic Syndrome: Molecular Mechanisms and Clinical Implications |
Source documents